Welcome to our dedicated page for Karuna Therapeutics news (Ticker: KRTX), a resource for investors and traders seeking the latest updates and insights on Karuna Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Karuna Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Karuna Therapeutics's position in the market.
Karuna Therapeutics (NASDAQ: KRTX) announced its Q3 2020 financial results and business updates, reporting a net loss of $18.8 million, up from $9.0 million in Q3 2019, primarily due to increased R&D expenses of $12.6 million. The company is set to begin its Phase 3 EMERGENT program for KarXT, targeting acute psychosis in schizophrenia, by the end of 2020. The current cash reserves of $344.9 million are expected to last for at least three years, supporting upcoming clinical trials and potential NDA submissions.